Certified-PEP Launches Two New Research Peptide Sites as Black Friday Peptide Deal Interest Builds

Nov 7, 2026

Black Friday Peptide Deals and Peptides For Sale put twelve lab-tested research compounds in one place as buyers get ready for the holiday sale season.

San Diego, United States, November 7, 2026 -- San Diego, CA – Certified-PEP is a research peptide company that supplies U.S.-made, research-use-only (RUO) peptides, and today it announced the launch of two new microsites: Black Friday Peptide Deals at https://blackfridaypeptidedeals.us.com/ and Peptides For Sale at https://peptidesforsale.us.com/. Each site gives researchers one organized page to browse twelve compounds from the Certified-PEP catalog, including BPC-157, TB-500, GLOW and KLOW, with a direct link to every product page.

The launch comes as excitement builds across the peptide market. With Black Friday arriving on November 27, researchers and lab buyers are looking for the best deals on peptides, and many want to compare options, volume savings and testing documentation before they order. The two new sites were built to make that comparison faster and clearer, with every product page lightning fast with a clean UX.

“Every year around Black Friday, researchers start hunting for the best deals on peptides, and this year the excitement in the market is hard to miss,” said Benson Jamison of Certified Peptides. “We wanted to give people a clear, easy place to see the full lineup, the volume savings and the lab testing behind every batch before they place an order.”

What Each Site Offers

  • Black Friday Peptide Deals collects twelve research peptides on a single deals page. Certified-PEP applies volume savings automatically at checkout: 5% off three to five vials of the same product and 10% off six or more.
  • Peptides For Sale is a collection page for the same twelve compounds, organized by category (repair, blends, growth and metabolic) alongside the lyophilized vials, capsules, lipotropics and bundles in the wider Certified-PEP catalog.
  • Both sites include a research library and a certificate of analysis (COA) guide that explains how to read a lab report.

Researchers should watch for price adjustments of 30-40% with the upcoming holiday. Prices, promotions and availability are set by Certified-PEP and may change without notice.

Testing and Transparency

Certified-PEP emphasizes U.S. manufacturing in a cGMP-compliant facility and independent, batch-specific testing, most often through Vanguard Laboratory, an ISO/IEC 17025:2017 accredited lab. Every vial carries a QR code that opens that lot’s report on the testing lab’s own website. The company reports more than 200,000 orders filled and more than 7,000 verified customer reviews.

A Fast-Growing Category

Public interest in peptides is growing quickly:

  • A November 2025 KFF poll found about 1 in 8 U.S. adults (12%) said they were taking a peptide.
  • A May 2026 Hone Health survey of 2,491 peptide-aware U.S. adults found 83% support letting licensed compounding pharmacies make popular peptides with a prescription. 39% said FDA reclassification would be the biggest reason they would try peptides or use them more.
  • New Beauty’s 2026 State of Aesthetics research found only 12.3% of beauty consumers recognize BPC-157, even as 47.9% of peptide users spend $1,000 or more a year on peptide therapies or weight-loss drugs.
  • Grand View Research valued the global peptide therapeutics market at $140.9 billion in 2025 and projects it will reach $294.6 billion by 2033. That figure is driven largely by approved drugs such as GLP-1s, not research peptides.

The Regulatory Picture

The regulatory landscape is also changing. In April 2026, the FDA removed 12 peptides from its Category 2 “significant safety risk” list, including BPC-157, TB-500, KPV, and injectable GHK-Cu. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend BPC-157, TB-500, and KPV for the 503A bulk drugs list. Injectable GHK-Cu is due for review before the end of February 2027.

Removal from Category 2 does not make a peptide approved or eligible for compounding. All Certified-PEP products are sold strictly for laboratory research use and are not for human consumption.

New Research Content

Both sites are publishing educational material for researchers, including guides to reading a peptide COA and choosing a peptide supplier.

Learn More

To browse the Black Friday lineup or explore the full collection, visit the two sites listed above.

Certified-PEP is a U.S.-based supplier of peptides and compounds for qualified laboratory research. The company emphasizes U.S. manufacturing, batch-specific analytical testing through Vanguard Laboratory, product labeling with COA information, transparent research documentation and top-tier customer service. Certified-PEP products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use or clinical applications.

Research Use Only: Certified-PEP products are intended solely for in-vitro laboratory research and are not intended for human or veterinary use, consumption, clinical use, diagnosis, treatment or prevention of disease. Statements in this release have not been evaluated by the U.S. Food and Drug Administration.

About Certified PEP

Black Friday Peptide Deals and Peptides For Sale are resource sites that list twelve research compounds from the Certified-PEP catalog, with organized educational content, COA guidance and links to each product page. All products referenced are intended solely for in-vitro laboratory research and are not intended for human or veterinary use or clinical applications. No dosing or administration guidance is provided.

Contact Info:
Name: Benson Jamison
Email: Send Email
Organization: Certified PEP
Phone: 8058893321
Website: https://certified-pep.com/

Release ID: 89208818

Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.

More News

Trump Appeals Dismissal of $10 Billion Libel Suit Against Wall Street Journal
Nov 6, 2026
Trump Appeals Dismissal of $10 Billion Libel Suit Against Wall Street Journal

A judge has twice tossed the president’s defamation complaint, which centered on an article about a birthday greeting to the sex offender Jeffrey Epstein.

AI stocks climb after trillions wiped from market values
Nov 6, 2026
AI stocks climb after trillions wiped from market values

Investors had been selling off tech shares in part due to concerns the Democrat election victory would mean slower AI development.

How Farmers’ Frustration With Trump’s Policies Helped Democrats
Nov 6, 2026
How Farmers’ Frustration With Trump’s Policies Helped Democrats

Anger over tariffs and higher costs because of the war in Iran led many Republican farmers and ranchers to vote blue — or stay home.

They Spent Millions to Keep Their Dream Cruise Afloat. It Died Anyway.
Nov 6, 2026
They Spent Millions to Keep Their Dream Cruise Afloat. It Died Anyway.

Secrecy, debt and soaring fuel costs all contributed to the Odyssey’s downfall. Here’s an inside look at how the “endless cruise” unraveled.

Why the US midterms sparked an AI stock selloff
Nov 6, 2026
Why the US midterms sparked an AI stock selloff

Fears of more AI regulation appear to have sparked fear among investors, but concerns about the industry have been growing for some time.

Tesla Is Ending Production of Its Cybertruck and Refocusing on the Cybercab
Nov 6, 2026
Tesla Is Ending Production of Its Cybertruck and Refocusing on the Cybercab

Production of the electric trucks will stop in the middle of 2027 to make room for increased production of its autonomous ride-share vehicle, Elon Musk said.

Why smoky bacon crisps threaten to reignite rows over EU rules
Nov 6, 2026
Why smoky bacon crisps threaten to reignite rows over EU rules

A post-Brexit deal on food standards has raised questions over the future naming of the classic British snack.

What Shaped Anthropic CEO Dario Amodei’s Thinking on A.I.
Nov 6, 2026
What Shaped Anthropic CEO Dario Amodei’s Thinking on A.I.

Some call him a doomer. Others see him as a responsible technologist. Here’s how Dario Amodei’s thinking on artificial intelligence was shaped.

Food bank to close amid rising costs
Nov 6, 2026
Food bank to close amid rising costs

A food bank in Goole annouces it will close in January as costs rise and donations drop.

Winter support for residents facing cost pressures
Nov 6, 2026
Winter support for residents facing cost pressures

The plans aim to help more people access food, financial advice and help with heating costs.

A.I. Was Supposed to Come for Our Jobs. So Far, Evidence Is Mixed.
Nov 6, 2026
A.I. Was Supposed to Come for Our Jobs. So Far, Evidence Is Mixed.

White collar industries that are most exposed to artificial intelligence continued to add jobs in October, although that growth has been weak.

PM tells firms to publish salaries in job adverts ahead of new law
Nov 6, 2026
PM tells firms to publish salaries in job adverts ahead of new law

The government argues the change will help jobseekers and could help to prevent pay discrimination.

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Marketers Log

Marketers Log is your personal Business & Finance news site to provide marketing or market-related news.

Newsletter